Substance use disorders (SUDs) are highly comorbid with HIV infection, necessitating an understanding of the interactive effects of drug exposure and HIV. The relationship between progressive HIV infection and cocaine use disorder is likely bidirectional, with cocaine use having direct effects on immune function while HIV infection can alter addiction-related behavior. To better characterized the neurobehavioral and immune consequences of HIV infection and cocaine exposure, this study utilized a humanized mouse model to investigate the outcomes of progressive HIV infection on cocaine-related behaviors in a cocaine conditioned place preference (CPP) model, and the interactive effects of cocaine and HIV infection on peripheral and central nervous system inflammation. HIV infection did not impact the formation of a cocaine CPP, but did result in resistance to extinction of the CPP. No effects of HIV on yohimbine-primed reinstatement or cocaine seeking under conflict were observed. These behavioral alterations were accompanied by immune changes in HIV infected mice, including increased prefrontal cortex astrocyte immunoreactivity and brain-region specific effects on microglia number and reactivity. Peripheral immune system changes were observed in both mouse and human markers. Among other targets, this included HIV-induced reductions in mouse IL-1α and G-CSF and human TNFα and cocaine-induced alterations in human TNFα and mouse GM-CSF such that cocaine exposure increases both cytokines only in the absence of HIV infection. Together these data provide new insights into the unique neurobehavioral processes underlying HIV infection and cocaine use disorders, and further how they interact to effect immune responses.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462035 | PMC |
http://dx.doi.org/10.1101/2023.08.11.552858 | DOI Listing |
Curr HIV/AIDS Rep
January 2025
Columbia University Irving Medical School, New York, NY, USA.
Purpose: This narrative review addresses post-2020, specific, complex challenges for use of and adherence to pre-exposure prophylaxis (PrEP) for HIV prevention among out-of-treatment people who use drugs (PWUD) at syringe services programs (SSPs).
Recent Findings: The COVID-19 pandemic and its associated changes to the provision of healthcare have significantly impacted HIV prevention, especially for PWUD. Through a synthesis of literature and clinical experience, we (1) characterize the operational changes imposed by the pandemic on SSPs that shaped the current HIV prevention landscape; (2) describe three levels of current challenges for PWUD, including consumer attitudes, non-medical and medical provider attitudes, and structural and scalability barriers; (3) characterize current models for PrEP in SSPs; and (4) offer practical recommendations for HIV prevention in harm reduction programs.
AIDS Behav
January 2025
School of Public Health, Xinjiang Medical University, Xinjiang, 830011, China.
Anal HPV infection is particularly prevalent among men who have sex with men (MSM). The purpose of this study was to understand the status and influencing factors of HPV infection in MSM in Urumqi, Xinjiang, in order to provide suggestions for policy formulation. A prospective cohort study was conducted among HIV-negative MSM in Urumqi Xinjiang between April 2016 and June 2023.
View Article and Find Full Text PDFRev Med Suisse
January 2025
Unité VIH/sida, Service des maladies infectieuses, Département de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14.
The year 2024 saw many advances in HIV care, both in terms of treatment and prevention. The cure of a patient from Geneva made headlines and helped in understanding the complex immunology of the HIV virus. Long-acting injectable treatments improve the quality of life of peoplewith HIV (PWHIV) and area promising option for pre-exposure prophylaxis (PreP).
View Article and Find Full Text PDFRev Med Suisse
January 2025
Service de dermatologie et vénéréologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
This article focuses on two key innovations in dermatology: post-exposure prophylaxis for sexually transmitted infections (STIs) and new therapeutic options for inflammatory skin diseases. New European and American guidelines for doxycycline post-exposure prophylaxis (Doxy PEP) aim to prevent STIs in men who have sex with men (MSM) and individuals on HIV pre-exposure prophylaxis (PrEP). Doxy PEP is effective against syphilis and chlamydia, but its efficacy is limited by growing gonorrhea resistance.
View Article and Find Full Text PDFAging Cell
January 2025
Department of Internal Medicine and Radboud Center of Infectious Diseases, Radboudumc, Radboud University, Nijmegen, The Netherlands.
Due to the increased burden of non-AIDS-related comorbidities in people living with HIV (PLHIV), identifying biomarkers and mechanisms underlying premature aging and the risk of developing age-related comorbidities is a priority. Evidence suggests that the plasma proteome is an accurate source for measuring biological age and predicting age-related clinical outcomes. To investigate whether PLHIV on antiretroviral therapy (ART) exhibit a premature aging phenotype, we profiled the plasma proteome of two independent cohorts of virally suppressed PLHIV (200HIV and 2000HIV) and one cohort of people without HIV (200FG) using O-link technology.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!